Michaela Mattheus

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial”.

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

Journal of the American Heart Association(2020)10.1161/jaha.120.016976

N/A

2.4DataRank · unranked

74 citations

Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus +5 more

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine(2015)10.1056/nejmoa1504720

N/A

1.4DataRank · unranked

11839 citations

Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel +7 more

Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial

Diabetes Obesity and Metabolism(2023)10.1111/dom.14991

N/A

0.241DataRank · unranked

4 citations

Ahmed A. Kolkailah, Darren K. McGuire, Mark A. Espeland, Michaela Mattheus, Egon Pfarr +4 more

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kidney International(2020)10.1016/j.kint.2020.10.031

N/A

0DataRank · unranked

212 citations

Matthew R. Weir, George L. Bakris, Michaela Mattheus, David Z.I. Cherney, Naveed Sattar +8 more

Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction

Nature Cardiovascular Research(2025)10.1038/s44161-025-00657-7

N/A

0DataRank · unranked

3 citations

Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker, Josephine Harrington, W. Schuyler Jones +8 more

Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

ESC Heart Failure(2025)10.1002/ehf2.15393

N/A

0DataRank · unranked

1 citations

Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington +19 more